The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer

Metastatic Breast Cancer Clinical Trial

— PROOF  

Official title:

The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02072512
• Other study ID #: 307BC ET-01
• Status: Recruiting
• Phase: Phase 2
• First received: February 7, 2014
• Last updated: February 24, 2014
• Start date: January 2014
• Est. completion date: December 2016

Study information

• Verified date: February 2014
• Source: Hospital Affiliated to Military Medical Science, Beijing
• Contact: Zefei Jiang, Ph.D
• Phone: 8610-66947171
• Email: jiangzf[@]hotmail.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy of goserelin plus fulvestrant 500mg comparing with goserelin plus anastrozole as first line endocrine therapy for pre- and perimenopausal HR+ advanced breast cancer.

Description:

Premenopausal advanced breast cancer patients who failed tamoxifen treatment are possible good candidates for ovarian ablation/suppression and aromatase inhibitors.Fulvestrant has been studied little in premenopausal women despite of its attractive mechanism of actions. Based on this rationale, we introduced high-dose of fulvestrant with LHRH agonist as a randomized trial comparing with AI plus LHRH agonist.

To assess efficacy of goserelin plus fulvestrant 500mg comparing with goserelin plus anastrozole as first line endocrine therapy for pre- and perimenopausal HR+ advanced breast cancer in terms of progression-free survival(PFS)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: December 2016
• Est. primary completion date: November 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Signed informed consent document on file.

2. All patients must be female with age>18 and premenopausal or perimenopausal.

3. Patients must have an ECOG performance status of 0, 1, or 2.

4. Patients with life expectancy of more than 3 months.

5. Patients with metastatic or locally advanced disease not amenable to therapy with curative intent.

6. Histological/cytological confirmation of breast cancer. Patients must have either positive estrogen and/or progesterone receptor determination by IHC or competitive binding assay on advanced disease, or if not performed on their advanced disease a positive result on their primary breast cancer specimen (Positivity is defined as an Allred score from 3 to 8 by IHC or at least 1% positive tumor nuclei in the sample in the presence of expected reactivity of internal and external controls [35]).

7. Patients who recurred on or after completion of adjuvant tamoxifen therapy(with or without GnRHa). Toremifene could be substituted for tamoxifen in adjuvant setting.

8. Duration of adjuvant tamoxifen(toremifene) treatment should be at least 48 weeks or more.

9. Patients with measurable lesion at baseline, or Patients with bone lesions, lytic or mixed (lytic + sclerotic), in the absence of measurable disease as defined by RECIST 1.1 criteria

10. Patients may receive irradiation to any bony sites of disease for pain control or for prevention of fracture.

11. For women of childbearing potential, agreement to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner and to continue its use for the duration of study treatment and for 6 months after the last dose of study treatment.

Exclusion Criteria:

1. Presence of life-threatening metastatic visceral disease, defined as extensive hepatic involvement, or any degree of brain or leptomeningeal involvement (past or present), or symptomatic pulmonary lymphangitic spread. Patients with discrete pulmonary parenchymal metastases are eligible, provided their respiratory function is not compromised as a result of disease.

2. Postmenopausal woman, defined as a woman fulfilling any 1 of the following criteria:

• Age .60 years

• Prior bilateral oophorectomy

• Age<60 years and amenorrheic for 12 or more months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and FSH and estradiol in the postmenopausal range(according to local sites).

• If taking tamoxifen or toremifene, and age<60 years, then FSH and plasma estradiol level in postmenopausal ranges(according to local sites).

3. More than one regimen of chemotherapy for advanced disease.

4. Previous endocrine therapy for advanced disease.

5. Prior treatment with an aromatase inhibitor or fulvestrant.

6. Prior treatment with a GnRHa within 3 months.

7. Treatment with a non-approved or experimental drug within 4 weeks before randomisation.

8. Current or prior malignancy within previous 3 years (other than breast cancer or adequately treated basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix).

9. History of bleeding diathesis (i.e., disseminated intravascular coagulation [DIC], clotting factor deficiency), or long-term anticoagulant therapy.

10. Known hypersensitivity to the active substance or to any of the excipients of this product, or other GnRHa.

11. HER-2 over-expressing breast cancer and concomitant trastuzumab treatment.

12. Pregnancy and lactation.

13. Any severe concomitant condition which makes it undesirable for the patient to participate in t he trial or which would jeopardize compliance with the trial protocol. e.g., uncontrolled cardiac disease, uncontrolled diabetes mellitus, severe osteoporosis or renal failure and so on .

14. Inadequate organ function

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer

Intervention

Drug:
• Fulvestrant
Fulvestrant 500mg I.M. Once/28days,until progression or unacceptable toxicity develops
• Goserelin
goserelin 3.6mg subcutaneously every 28(± 3) days
• Anastrozole
Anastrozole 1mg P.O. once daily, until progression or unacceptable toxicity develops
• Goserelin
goserelin 3.6mg subcutaneously every 28(± 3) days

Locations

Country	Name	City	State
China	307 Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Hospital Affiliated to Military Medical Science, Beijing

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	the duration of response of patients treated with goserelin plus fulvestrant 500mg and duration of response of patients treated with goserelin plus anastrozole.		Participants will be followed for an expected average of 1 year.	No
Other	the duration of clinical benefit of patients treated with goserelin plus fulvestrant 500mg and duration of clinical benefit of patients treated with goserelin plus anastrozole.		Participants will be followed for an expected average of 1 year.	No
Other	the safety and tolerability(by NCI CTCAE v4.0) of goserelin plus fulvestrant 500mg compared with goserelin plus anastrozole.		Participants will be followed for an expected average of 1 year.	No
Primary	the efficacy of goserelin plus fulvestrant 500mg and the efficacy of goserelin plus anastrozole as first line endocrine therapy for pre- and perimenopausal HR+ advanced breast cancer in terms of progression-free survival(PFS)	Primary endpoint is progression-free survival. Progression-free survival (PFS) is defined as the time elapsed between randomization and tumor progression(by RECIST version 1.1) or death from any cause	Progression-free survival (PFS) is defined as the time elapsed between randomization and tumor progression(by RECIST version 1.1) or death from any cause.Participants will be followed for an expected average of 1 year.	No
Secondary	the overall response rate(by RECIST version 1.1) of patients treated with goserelin plus fulvestrant 500mg and the overall response rate of patients treated with goserelin plus anastrozole.	to compare overall response rate of patients treated with goserelin plus fulvestrant 500mg with overall response rate of patients treated with goserelin plus anastrozole.	Participants will be followed for an expected average of 1 year.	No
Secondary	the clinical benefit rate of patients treated with goserelin plus fulvestrant 500mg and clinical benefit rate of patients treated with goserelin plus anastrozole.		Participants will be followed for an expected average of 1 year.	No